Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients

HIV Clinical Trials

Volumn 13, Issue 2, 2012, Pages 70-82

  Chung, Raymond T ^a   Umbleja, Triin ^b   Chen, Jennifer Y ^c   Andersen, Janet W ^b   Butt, Adeel A ^d   Sherman, Kenneth E ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

extended therapy; HCV; HIV; weight based ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; AGE; ANEMIA; ANTIVIRAL THERAPY; BODY WEIGHT; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN AMERICAN; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; BODY WEIGHT; COINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK FACTORS;

EID: 84859871673     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1302-70     Document Type: Review

References (33)

1. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(suppl 1):S77-84.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
3. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
4. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
7. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA. 2004;292:2839-2848.
11. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007;46:1688-1694.
12. Brouwer JT, Nevens F, Bekkering FC, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol. 2004;40:689-695.
13. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-1097.
14. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon- alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-460.
15. Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52:1201-1207.
16. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response [published online ahead of print November 10, 2009). Gastroenterology. 2010;138:503-512, 512 e1.
17. Sherman KE, Shire NJ, Rouster SD, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virusinfected patients. Gastroenterology. 2005;128:313-327.
18. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIVcoinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010;55(5):597-605.
19. Andersson K, Chung RT. Hepatitis C virus in the HIVinfected patient. Clin Liver Dis. 2006;10:303-320, viii.
20. Van den Eynde E, Tiraboschi JM, Tural C, et al. Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS. 2010;24:975-982.
21. Nunez M, Miralles C, Berdun MA, et al. Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-982.
22. Uriel A, Moorehead L, Carriero D, Sulkowski M, Dieterich D; Hepatitis Resource Network Clinical Trials Group. A multicenter, randomized trial of 48 vs 72 weeks of peginterferon- alpha-2B + ribavirin in HIV/HCV co-infected subjects: Longer therapy does not correlate with improved sustained virologic response. Presented at: Conference of Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado.
23. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007;22:832-836.
24. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954-960.
25. Nunez M, Marino A, Miralles C, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCVcoinfected patients. J Acquir Immune Defic Syndr. 2007;45:439-444.
26. Martin-Carbonero L, Nunez M, Marino A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2008;22:15-21.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
28. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.
29. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51:788-795.
30. Iadonato SP, Katze MG. Genomics: Hepatitis C virus gets personal. Nature. 2009;461:357-358.
31. Chung RT. Reaping the early harvest of the genomics revolution. Gastroenterology. 2010;138:1653-1654.
32. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
33. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.